TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2662981

Group type: EXPERIMENTAL
Intervention: Active management of the third stage of labor
Number of subjects: 240

Group type: COMPARATOR
Intervention: Physiologic management of the third stage of labor
Number of subjects: 240
Study: 31142242

Group type: EXPERIMENTAL
Intervention: Combination therapy of vitamin C, thiamine and hydrocortisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone monotherapy
Number of subjects: 0
Study: 28545508

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Double-blind placebo (DBP)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Peppermint oil
Number of subjects: 280
Study: 25311423

Group type: EXPERIMENTAL
Intervention: Dexamethasone (short-term, high-dose, perioperative use)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 24
Study: 23521917

Group type: EXPERIMENTAL
Intervention: Ipilimumab treatment
Number of subjects: 162
Study: 21849187

Group type: EXPERIMENTAL
Intervention: Acute androgen suppression therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chronic androgen suppression therapy
Number of subjects: 50
Study: 19302649

Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glidescope
Number of subjects: 60
Study: 17394073

Group type: EXPERIMENTAL
Intervention: 100-cm upper endoscope
Number of subjects: 81

Group type: COMPARATOR
Intervention: 60-cm sigmoidoscope
Number of subjects: 81
Study: 15446534

Group type: EXPERIMENTAL
Intervention: Closed reduction
Number of subjects: 102

Group type: COMPARATOR
Intervention: Open reduction
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both groups (closed and open reduction)
Number of subjects: 102
Study: 11441324

Group type: EXPERIMENTAL
Intervention: Zinc lozenges (four to six lozenges/day for 10 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9671436

Group type: EXPERIMENTAL
Intervention: 1% N-chlorotaurine (NCT) applied for five days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 2.8% NCT applied for five days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 1% and 3% NCT regimen applied for nine days in rabbits
Number of subjects: 14
Study: 7675378

Group type: EXPERIMENTAL
Intervention: PGE2 pessary
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo pessary
Number of subjects: 155
Study: 2291748

Group type: EXPERIMENTAL
Intervention: Standardized garlic-powder tablets (800 mg daily for 16 weeks)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo tablets (same number as garlic tablets for 16 weeks)
Number of subjects: 261
Study: 6157050

Group type: EXPERIMENTAL
Intervention: Streptokinase for 24 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 0
Study: 30148436

Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28865799

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 200 mg PO
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 400 mg PO
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate 600 mg PO
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tedizolid phosphate (all doses)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 26362172

Group type: EXPERIMENTAL
Intervention: High-dose trivalent inactivated influenza vaccine
Number of subjects: 31989
Study: 23702263

Group type: EXPERIMENTAL
Intervention: Fasted participants (intervention group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-fasted participants (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Eating manipulation (fasting before testing)
Number of subjects: 80
Study: 20979461

Group type: EXPERIMENTAL
Intervention: E2+DRSP (17β‐estradiol 1 mg/day plus drospirenone 2 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Calcium (control)
Number of subjects: 100
Study: 19489490

Group type: EXPERIMENTAL
Intervention: Acupuncture intervention in group A
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Acupuncture intervention in group B
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Acupuncture intervention in group C
Number of subjects: 279

Group type: COMPARATOR
Intervention: Control group (Prednisone only)
Number of subjects: 279
Study: 17203481

Group type: EXPERIMENTAL
Intervention: Continuous wave (CW) EMF exposure (0.25 W)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pulsed modulated (PM) EMF exposure (mean 0.25 W)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham EMF exposure (control group of 16 subjects)
Number of subjects: 36
Study: 15019795

Group type: COMPARATOR
Intervention: Healthy normally cycling women (Control)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Women with major depression (Intervention)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Fluoxetine (sub-analysis)
Number of subjects: 27
Study: 11705426

Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 234
Study: 9270575

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 8001289

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody-based enzyme immunoassay (EIA) for urinary 18-hydroxycortisol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Post-adrenalectomy urinary 18-hydroxycortisol level
Number of subjects: 27
Study: 3078281

Group type: EXPERIMENTAL
Intervention: Oral trifluoperazine (TFP) 7 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Inhaled trifluoperazine (TFP) 10 mg/ml, nebulized for 5 min
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline (control for inhaled TFP)
Number of subjects: 14
Study: 30714059

Group type: EXPERIMENTAL
Intervention: Bristleless toothbrush
Number of subjects: 23

Group type: COMPARATOR
Intervention: Soft nylon-bristled toothbrush
Number of subjects: 23
Study: 28262330

Group type: EXPERIMENTAL
Intervention: Paracetamol prophylaxis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen prophylaxis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no prophylaxis)
Number of subjects: 0
Study: 26321734

Group type: EXPERIMENTAL
Intervention: Computerized cognitive training application
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 22970725

Group type: EXPERIMENTAL
Intervention: Lung volume recruitment (LVR)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 29
Study: 19954996

Group type: EXPERIMENTAL
Intervention: Muscle flap group (intercostal muscle flap + intracostal suture)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (intracostal suture only)
Number of subjects: 144
Study: 19142041

Group type: EXPERIMENTAL
Intervention: Sham kinesiology treatment (administered weekly for 5 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Real kinesiology treatment (4 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham kinesiology treatment (4 sessions)
Number of subjects: 20
Study: 16324923

Group type: EXPERIMENTAL
Intervention: glyburide (10 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: glimepiride (4 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 14689407

Group type: EXPERIMENTAL
Intervention: Preoperative cardiac stress testing
Number of subjects: 99

Group type: COMPARATOR
Intervention: No stress testing (Control)
Number of subjects: 99
Study: 11081528

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (n=63)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo (n=61)
Number of subjects: 124
Study: 8885811

Group type: EXPERIMENTAL
Intervention: Specific IgE antibodies to food allergens (egg white, fish, wheat, peanut, soy, milk)
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Symptoms of food intolerance
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Specific IgE antibodies to food allergens
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Symptoms related to food allergens
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Atopic subjects, subjects with current asthma, and subjects with bronchial hyperresponsiveness
Number of subjects: 1812
Study: 1525984

Group type: EXPERIMENTAL
Intervention: Tablets containing 90% USRDA of Mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tablets containing 180% USRDA of Mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 4091884

Group type: EXPERIMENTAL
Intervention: Ticlopidine treatment (500 mg/day) for 30 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 30682576

Group type: EXPERIMENTAL
Intervention: Mindset that non-life-threatening symptoms can signal desensitization
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mindset that non-life-threatening symptoms are unfortunate side effects of treatment
Number of subjects: 50
Study: 30307416

Group type: EXPERIMENTAL
Intervention: Fast track rehabilitation (FTR)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation)
Number of subjects: 86
Study: 26832780

Group type: COMPARATOR
Intervention: Placebo varnish (control)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: elmex® fluid
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fluor Protector S
Number of subjects: 90
Study: 25270426

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 168

Group type: COMPARATOR
Intervention: U.S. Food and Drug Administration recommended pharmacologic treatments (RPT)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual Care (TAU)
Number of subjects: 168
Study: 22828681

Group type: EXPERIMENTAL
Intervention: Caudal epidural injections of local anesthetic (lidocaine 0.5%)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Caudal epidural injections of 0.5% lidocaine mixed with 1 mL of steroid
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall results for both groups
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Average relief per procedure
Number of subjects: 120
Study: 20663275

Group type: EXPERIMENTAL
Intervention: Specific inspiratory muscle training (IMT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Deep breathing exercises
Number of subjects: 80

Group type: COMPARATOR
Intervention: Incentive spirometry
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 80
Study: 17440642

Group type: EXPERIMENTAL
Intervention: Broad-spectrum immune modulatory therapy
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400
Study: 15116072

Group type: EXPERIMENTAL
Intervention: Moderately high intake of zinc (811 micromol/day; 53 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Low dietary zinc (45.9 micromol/day; 3 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High dietary zinc (811 micromol/day; 53 mg/day)
Number of subjects: 28
Study: 12008939

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antithrombotic prophylaxis (stopped at hospital discharge)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis extended to 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis extended to 6 weeks
Number of subjects: 0
Study: 9823995

Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy (DOT)
Number of subjects: 319

Group type: COMPARATOR
Intervention: Self-Administered Therapy (SAT)
Number of subjects: 319
Study: 8088198

Group type: EXPERIMENTAL
Intervention: Chinese herbs (A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ear-acupuncture (B)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Epidural morphine (C)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chinese herbs (A) and Ear-acupuncture (B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 2733993

Group type: EXPERIMENTAL
Intervention: Low dose oral colchicine (1.2 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin C (250 mg/day orally)
Number of subjects: 0
Study: 31660788

Group type: COMPARATOR
Intervention: General Anaesthesia (GA) alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA) with tumescent anaesthesia (G + T)
Number of subjects: 90
Study: 28168567

Group type: EXPERIMENTAL
Intervention: Extended targeted retinal photocoagulation (ETRP)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Conventional pan-retinal photocoagulation (CPRP)
Number of subjects: 270
Study: 27620647

Group type: EXPERIMENTAL
Intervention: Isocaloric meal with erythritol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control sucrose meal
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isovolumic meal with erythritol
Number of subjects: 20
Study: 24021298

Group type: EXPERIMENTAL
Intervention: Partial weight‐supported treadmill gait training (PWSTT) with unloading of 20% of body weight
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional gait training (CGT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (stable dosage of dopaminomimetic drugs only)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Partial weight‐supported treadmill gait training (PWSTT)
Number of subjects: 60
Study: 23750500

Group type: EXPERIMENTAL
Intervention: Cranberry juice (0.7 litres/day) for 60 days
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (n=36)
Number of subjects: 56
Study: 21294931

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (VAS) 50,000 IU (15 mg) at birth
Number of subjects: 4183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4183
Study: 19041130

Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 3526

Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 3526
Study: 16141379

Group type: EXPERIMENTAL
Intervention: 0.05% oxymetazoline (one puff per nostril)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study: 14675268

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once a morning
Number of subjects: 85

Group type: COMPARATOR
Intervention: Omeprazole 20 mg once a morning
Number of subjects: 85

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg once a morning
Number of subjects: 85
Study: 10721243

Group type: EXPERIMENTAL
Intervention: PG universal retraction springs
Number of subjects: 36

Group type: COMPARATOR
Intervention: Closed coil spring system
Number of subjects: 36
Study: 9187529

Group type: EXPERIMENTAL
Intervention: Selegiline (deprenyl)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study: 1435800

Group type: EXPERIMENTAL
Intervention: alpha-interferon (9 million units/m2 body surface area three times a week for four months)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: alpha-interferon
Number of subjects: 24
Study: 3157709

Group type: EXPERIMENTAL
Intervention: 2% erythromycin ointment
Number of subjects: 208

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 208
Study: 31554419

Group type: EXPERIMENTAL
Intervention: CXCL16 admission levels
Number of subjects: 5142

Group type: EXPERIMENTAL
Intervention: CXCL16 admission levels (adjusted)
Number of subjects: 5142

Group type: EXPERIMENTAL
Intervention: CXCL16 measured at 1 month
Number of subjects: 5142

Group type: EXPERIMENTAL
Intervention: Change in CXCL16 from admission to 1 month
Number of subjects: 5142
Study: 29980419

Group type: EXPERIMENTAL
Intervention: Anterolateral skin incision
Number of subjects: 118

Group type: COMPARATOR
Intervention: Anteromedial skin incision
Number of subjects: 118
Study: 27106640

Group type: EXPERIMENTAL
Intervention: 24-hour antibiotic group
Number of subjects: 112

Group type: COMPARATOR
Intervention: Extended antibiotic group
Number of subjects: 112
Study: 24806263

Group type: EXPERIMENTAL
Intervention: Zaleplon (10 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 23187987

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous ketamine
Number of subjects: 32
Study: 19643937

Group type: EXPERIMENTAL
Intervention: Energy efficiency upgrading in homes of COPD patients
Number of subjects: 178

Group type: COMPARATOR
Intervention: Independent energy efficiency action by patients
Number of subjects: 178
Study: 18403946

Group type: EXPERIMENTAL
Intervention: Ginger (1200 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 17158440

Group type: EXPERIMENTAL
Intervention: Fish-oil fatty acid esters of plant sterols (FO-PS)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sunflower oil esters of plant sterols (SU-PS)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (Olive Oil - OO)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 21
Study: 12715486

Group type: EXPERIMENTAL
Intervention: Profore (multilayer elastic compression)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Short-stretch compression
Number of subjects: 89
Study: 10634827

Group type: EXPERIMENTAL
Intervention: simvastatin + omega-3 fatty acids at 3.36 g/d
Number of subjects: 41
Study: 8939178

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg four times daily for 12 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Albuterol 0.2 mg four times daily for 12 weeks
Number of subjects: 32
Study: 1382927

Group type: EXPERIMENTAL
Intervention: Hemodilution therapy (by rapid venesection, venous infusion of autologous plasma and 500 ml dextran 40)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Hemodilution therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Hemodilution therapy and Standard therapy
Number of subjects: 92
Study: 3887882

Group type: EXPERIMENTAL
Intervention: Medically prescribed and supervised regular physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise regimen (frequency of attendance and intensity differed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular physical activity
Number of subjects: 0
Study: 31272313

Group type: EXPERIMENTAL
Intervention: Intensified ARV regimen
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Moderate number of ARV drug changes (up to 2 per 6 months)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Changes based on clinical/HIV-related reasons
Number of subjects: 368
Study: 27943511

Group type: EXPERIMENTAL
Intervention: Text2Quit
Number of subjects: 409

Group type: COMPARATOR
Intervention: Smoking cessation material (control)
Number of subjects: 409
Study: 26473333

Group type: EXPERIMENTAL
Intervention: High-dose TwHF (2.0 mg·kg·d)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Low-dose TwHF (1.5 mg·kg·d)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Mesalazine (3 g/d)
Number of subjects: 198
Study: 23003915

Group type: EXPERIMENTAL
Intervention: DOX-β-TCP + EDTA
Number of subjects: 30

Group type: COMPARATOR
Intervention: DOX-β-TCP
Number of subjects: 30
Study: 21586714

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (7000 μg of retinol equivalents as retinyl palmitate)
Number of subjects: 125257

Group type: EXPERIMENTAL
Intervention: Beta carotene supplementation (42 mg of all-trans beta carotene)
Number of subjects: 125257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125257

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 125257

Group type: EXPERIMENTAL
Intervention: Beta carotene supplementation
Number of subjects: 125257
Study: 19095033

Group type: EXPERIMENTAL
Intervention: dTpa
Number of subjects: 100

Group type: COMPARATOR
Intervention: Td+pa
Number of subjects: 100
Study: 16723217

Group type: EXPERIMENTAL
Intervention: Levocetirizine 5mg
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study: 14688378

Group type: EXPERIMENTAL
Intervention: CML66-L peptide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CML66-L
Number of subjects: 0
Study: 11903320

Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension (DASH) trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight control and sodium restriction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary fish and weight control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary protein and fibre
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular coffee drinking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary anti-oxidants
Number of subjects: 0
Study: 9356116

Group type: EXPERIMENTAL
Intervention: Midazolam (M) 36 microg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fentanyl (F) 2.4 microg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both (B) 0.6 microg/kg F, 9 microg/kg M
Number of subjects: 24
Study: 8160279

Group type: EXPERIMENTAL
Intervention: IgM-enriched immunoglobulin (5 ml/kg/d for three days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (standard treatment with antibiotics and fresh plasma/whole blood transfusions)
Number of subjects: 44
Study: 3947216

Group type: EXPERIMENTAL
Intervention: Moxalactam disodium
Number of subjects: 163

Group type: COMPARATOR
Intervention: Clindamycin phosphate and tobramycin sulfate
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Colon injuries
Number of subjects: 163
Study: 29488676

Group type: EXPERIMENTAL
Intervention: Insulin alone or in combination with oral hypoglycaemic drugs; prescribed to 24.4% to 34.5% of patients with diabetes.
Number of subjects: 24012

Group type: EXPERIMENTAL
Intervention: Insulin prescription in the administrative registry.
Number of subjects: 24012
Study: 27600290

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 448

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Non-diabetic patients
Number of subjects: 448